Provided by Tiger Fintech (Singapore) Pte. Ltd.

Poseida Therapeutics, Inc.

9.50
0.0000
Volume:- -
Turnover:203.93M
Market Cap:928.85M
PE:-14.95
High:9.50
Open:9.50
Low:9.50
Close:9.50
Loading ...

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

PR Newswire
·
12 Nov 2024

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
09 Nov 2024

Poseida Therapeutics Inc reports results for the quarter - Earnings Summary

Reuters
·
09 Nov 2024

Poseida Therapeutics holds virtual R&D Day

TIPRANKS
·
09 Nov 2024

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Poseida Therapeutics (PSTX) and Evolus (EOLS)

TIPRANKS
·
08 Nov 2024

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

Benzinga
·
08 Nov 2024

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

THOMSON REUTERS
·
08 Nov 2024

Poseida Therapeutics Q3 Net Income USD 20.235 Million

THOMSON REUTERS
·
08 Nov 2024

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

PR Newswire
·
08 Nov 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

PR Newswire
·
06 Nov 2024

Poseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema

TIPRANKS
·
24 Oct 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

PR Newswire
·
24 Oct 2024

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Simply Wall St.
·
19 Oct 2024

Poseida Therapeutics: Buy Rating Affirmed Amid Financial Stability and Promising CAR-T Advancements

TIPRANKS
·
17 Oct 2024

Poseida Nominates New CAR-T Development Candidate, Triggering $15 Million Milestone Payment

MT Newswires Live
·
17 Oct 2024

BRIEF-Poseida Therapeutics Announces Nomination Of New Car-T Development Candidate Under Collaboration With Roche

Reuters
·
17 Oct 2024

Poseida Therapeutics Inc - Expects Funds to Last Into Early 2026

THOMSON REUTERS
·
17 Oct 2024

Poseida Therapeutics Inc - Nomination Triggers $15 Million Milestone Payment to Poseida

THOMSON REUTERS
·
17 Oct 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration With Roche

THOMSON REUTERS
·
17 Oct 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

PR Newswire
·
17 Oct 2024